DOCSLIB.ORG

Business Administration and Management

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Business Administration and Management Archives of Business Administration and Management York JM. Arch Bus Adm Manag: ABAM-105. Review Article DOI: 10.29011/ABAM-105. 100005 Examining the San Diego Venture Ecosystem John Michael York*1, Jin Cho2, Subbu Iyler3 1Orfalea College of Business, California Polytechnic State University, San Luis Obispo, USA 2Qualcomm, San Diego, CA 3ICW Group, San Diego, CA *Corresponding author: John Michael York, Pharm.D., M.B.A. Orfalea College of Business, California Polytechnic State Univer- sity, San Luis Obispo, USA. Tel: +18052382485; Email: [email protected] Citation: York JM (2018) Examining the San Diego Venture Ecosystem. Arch Bus Adm Manag: ABAM-105. DOI: 10.29011/ ABAM-105. 100005 Received Date: 18 March, 2018; Accepted Date: 06 April, 2018; Published Date: 17 April, 2018 Abstract In the recent decade, San Diego, California has become a hub for startup activity in multiple sectors including biotech- nology, cybertech, defense, energy, technology, and telecommunications. Ranked as one of the top places to launch a startup, it is the home to startup success including Acadia Pharmaceutical, Amylin, Gen-Probe, Illumina, ProFlowers, and Qualcomm. To understand the dynamics within this entrepreneurial community, the paper provides an overview of its venture ecosystem, defined as a mix of capabilities to support startup activity. It examines the research conducted to identify and discuss the key components within the community. These include major facilitators including trade organizations, accelerator/incubator programs, academia, private research institutes, city and state government, and key corporations. Then this paper will cover requisite support services including accounting, legal, insurance, human resources, and marketing, followed by a discussion of the real estate and financial capabilities to address the startup community needs. Afterwards, it will examine relationships within the community, strengths and weaknesses, and synergies. This review includes a comparison of San Diego’s ecosystem characteristics with that of the San Francisco/Silicon Valley and Los Angeles/Orange County regions. The paper closes with an assessment of ecosystem and prospects for the future. Keywords: Angel, Community capabilities, Entrepreneurship, San Diego, Startup, Venture capital, Venture ecosystem Introduction/Background Forbes Magazine 2014 article, he ranked San Diego as the best place to launch a startup [1]. San Diego has enjoyed the success of When one thinks about San Diego, what comes to mind? To its first-generation of startups in its telecommunications, software, many, it is about surf, sun, Shamu, and Sea World. To others, it is technology, and life sciences businesses. It is home to many about the San Diego Zoo, the Hotel Del, Petco Park, and Del Mar dynamic firms (Table 1). The success of several first-generation Racetrack. In business circles, most individuals do not think much startups has established now a foundation in San Diego for the about San Diego. To some, San Diego is a city trying to shake off next generation. Blockbuster successes, such as Qualcomm, have its Navy town and tourist reputation. To most business people, they transformed the communications and tech scene. Life sciences think of the convention center and the Gas Lamp District. Over the successes, such as Agouron, Amylin, IDEC, Illumina, ISIS, and last twenty years, San Diego has evolved. It has moved from a Thermo Fisher Scientific, have led some to rename San Diego as military and tourist town to a tech town. Since the 1990s, San Diego “biotech beach.” The emergence of such players in this space has has become a more diverse business community. Following the drawn outside corporations into the community. Today, AT&T, lead of Silicon Valley and the Bay area, San Diego has embraced Verizon, Samsung, Huawei, Pfizer, and Novartis maintain some innovation and entrepreneurial activity. In fact, in Tom Post’s commercial or research presence. 1 Volume 2018; Issue 01 Citation: York JM (2018) Examining the San Diego Venture Ecosystem. Arch Bus Adm Manag: ABAM-105. DOI: 10.29011/ABAM-105. 100005 Table 1: Examples of Companies Headquartered in San Diego Consumer Goods Continued Biotechnology Continued Apparel Biotechnology Sanford-Burnham Medical HD Supply Research Institute Reef sandals Abgent ProFlowers Sequenom Tribal Gear Acadia Pharmaceuticals WD-40 Company Quidel Corporation Bad Boy (brand) Accelrys Underground Toys, LLC Electronics Aethlon Medical Computer Software Defense Contracting American Technology Allerca Corporation Aonix AMN Healthcare Cubic e.Digital Corporation Axure Amylin Pharmaceuticals Inc. General Atomics Mad Catz, Inc. BackBone Apricus Biosciences Energy Chassis Plans DivX Arena Pharmaceuticals Envision Solar Entertainment ESET, NA Cytori Therapeutics Maxwell Technologies Daybreak Game Company FutureWave (acquired by Gen-Probe Macromedia) Sempra Energy Nautilus Entertainment Design Mitchell International Genesee Scientific San Diego Gas & Electric Genomics Institute of the Food and Drink Semantic Research Novartis Research Foundation Solar Turbines Silicon Beach (acquired by Aldus) Halozyme Therapeutics MobileOne AleSmith Brewing SweetLabs Illumina Ballast Point Brewing Events Company Peregrine Systems InvivoGen Chicken of the Sea (acquired by Hewlett-Packard) The Allstar Group Hash House a go go ServiceNow Nereus Pharmaceuticals Karl Strauss Brewing Websense Neurocrine Biosciences Finance and Insurance Teradata NuVasive Jack in the Box ResMed California Bank and Trust Rubio’s Fresh Mexican Grill Consumer Goods The Scripps Research Institute Commonwealth Financial Network Souplantation Salk Institute for Biological Dr. Bronner’s Magic Soaps Encore Capital Group Stone Brewing Studies 2 Volume 2018; Issue 01 Citation: York JM (2018) Examining the San Diego Venture Ecosystem. Arch Bus Adm Manag: ABAM-105. DOI: 10.29011/ABAM-105. 100005 Finance and Insurance Food and Drink Continued Continued San Diego City Beat Ryan Aeronautical LPL Financial Modern Times San Diego Jewish Journal Other San Diego Magazine Health Sports San Diego Reader Anacomp Arcturus Therapeutics BMC USA Times of San Diego Bridgepoint Education Ellsworth Handcrafted CareFusion Bicycles U-T San Diego Champion Ballroom Academy Dexcom Sector 9 Kyocera Retail NuVasive Bike Bandit Nth Generation Scripps Health Score Stream PETCO Peregrine Semiconductor Sharp HealthCare Telecommunications Quality Assurance Price Smart International Internet Cricket Communications Le Travel Store The Allen Group Satellite Internet Continuous Computing Considering the emergence of San Diego as a hub for entrepreneurial activity, this paper will explore this community’s MindTouch Jump Mobile venture ecosystem. First, this piece will outline our research into several of core elements that comprise the ecosystem: (1) Veoh Leap Wireless facilitators; (2) services; (3) real estate; (4) workforce; and (5) financial. Second, it will examine relationships within the SwoopThat.com Next Wave Wireless ecosystem, strengths and weaknesses, and comparisons to other ecosystems within California. Finally, the paper closes with Ignite Visibility Nokia UMT several observations related the community’s future as a startup community for entrepreneurs to consider. Novatel Wireless, Inc. Elements of The Ecosystem Media Facilitators Qualcomm The cornerstone of a robust ecosystem is the number of KSDY-LD Skyriver facilitators that support entrepreneurs through the startup journey. These organizations have helped startups from inception to initial McKinnon Broadcasting development to seed-stage funding to growth-stage funding. We Transportation and Logistics can segment facilitators into several groups and will examine and Mission Times Courier before further in this section. The major groups that function as National Steel and facilitators are summarized in (Table 2) include trade organizations, San Diego Business Journal Shipbuilding incubators/accelerators, the academic community, private research Transportation and Logistics institutes, government (city and state), and corporations. Media Continued Continued 3 Volume 2018; Issue 01 Citation: York JM (2018) Examining the San Diego Venture Ecosystem. Arch Bus Adm Manag: ABAM-105. DOI: 10.29011/ABAM-105. 100005 Table 2: Facilitators in the San Diego Ecosystem. Offices/Programs Tax Credits/Incentives SECTOR ORGANIZATION(S) CommNexus Innovation and Entrepreneurial Unit San Diego Business & Entrepreneurs Exchange New Employment Trade of the Governor’s San Diego Entrepreneurial Center & Startup Credit Organizations Business and Society California Competes State of San Diego Intellectual Property Law Association Economic California Development State of California Accelerators Incubators Department Board of Analytics Ventures EvoNexus (GO-Biz) Equalization Partial Connect Springboard Moxie Center (UCSD) Sales Tax California Innovation CyberHive StartR (UCSD) Hub (i-Hub) Exemption Von Liebig Center Incubators/ Hera Labs (UCSD) San Diego Accelerators/ Janssen Labs Wireless Health Hub School Programs Qualcomm Plug and Play San West Health Incubator Diego Key Huawei Qualcomm Institute Zahn Innovation Center Corporations (UCSD) (SDSU) Janssen Labs Qualcomm Robotics Lavin Center for Entre- Irvine Company Accelerator preneurship (SDSU) University of California San Diego (UCSD) Trade Organization San Diego State University (SDSU) As San Diego developed as a hub for telecommunications University of San Diego (USD) (e.g., Qualcomm, AT&T, and Verizon), CommNexus San Diego California
Load more

Recommended publications
  • Raising Angel & Venture Capital Finance
    Dr. Tom McKaskill Raising Angel & Venture Capital Finance AN ENTREPRENEUR’S GUIDE TO SECURING VENTURE FINANCE Angels and Venture Capital firms are in the business of generating a high rate of return on their investment, not in creating or building businesses. To be successful, the investor needs to achieve an exit of their investment within three to five years and that means planning the exit strategy from day one. The strategic trade sale is the preferred investment exit method. The business plan sets out the operational detail of how the firm will create the necessary conditions for achieving the exit for the investor. If you can’t create the necessary platform for an Initial Public Offering, you are going to have to sell your business. The author hereby gives permission for any recipient of this publication to reproduce, store in a retrieval system, transmit in any form or distribute by any means for personal use of any recipient. This publication may not be sold or resold for any fee, price or charge without the permission of the copyright owner. Raising Angel & Venture Capital Finance ii Testimonials ‘Many entrepreneurs have achieved great success by partnering with Angel investors but they need to have the right business venture and the right approach to external investment to attract investors. This book provides the essential guide for anyone contemplating seeking Angel investment.’ – John Mactaggart, Chairman Australian Association of Angel Investors ‘Through his experiences as a successful startup entrepreneur, business school professor, advisor and author, Dr. McKaskill provides some great insights and a comprehensive game plan for companies seeking Angel and VC funding.
    [Show full text]
  • The Handbook of Financing Growth
    ffirs.qxd 2/15/05 12:30 PM Page iii The Handbook of Financing Growth Strategies and Capital Structure KENNETH H. MARKS LARRY E. ROBBINS GONZALO FERNÁNDEZ JOHN P. FUNKHOUSER John Wiley & Sons, Inc. ffirs.qxd 2/15/05 12:30 PM Page b ffirs.qxd 2/15/05 12:30 PM Page a Additional Praise For The Handbook of Financing Growth “The authors have compiled a practical guide addressing capital formation of emerging growth and middle-market companies. This handbook is a valuable resource for bankers, accountants, lawyers, and other advisers serving entrepreneurs.” Alfred R. Berkeley Former President, Nasdaq Stock Market “Not sleeping nights worrying about where the capital needed to finance your ambitious growth opportunities is going to come from? Well, here is your answer. This is an outstanding guide to the essential planning, analy- sis, and execution to get the job done successfully. Marks et al. have cre- ated a valuable addition to the literature by laying out the process and providing practical real-world examples. This book is destined to find its way onto the shelves of many businesspeople and should be a valuable ad- dition for students and faculty within the curricula of MBA programs. Read it! It just might save your company’s life.” Dr. William K. Harper President, Arthur D. Little School of Management (Retired) Director, Harper Brush Works and TxF Products “Full of good, realistic, practical advice on the art of raising money and on the unusual people who inhabit the American financial landscape. It is also full of information, gives appropriate warnings, and arises from a strong ethical sense.
    [Show full text]
  • 20 13 Rep Or T
    2013 REPORT More Than 240 Medicines in Development for Leukemia, Lymphoma and Other Blood Cancers Every 4 minutes a person is diagnosed with leukemia, Medicines in Development lymphoma or For Leading Blood Cancers myeloma; Accounting for Application Submitted 9% of all cancers Phase III diagnosed each year Phase II Biopharmaceutical research companies • 15 each for myeloproliferative neo- Phase I are developing 241 medicines for blood plasms, such as myelofibrosis, poly- cancers—leukemia, lymphoma and cythemia vera and essential throm- 97 98 myeloma. This report lists medicines in bocythemia; and for myelodysplastic human clinical trials or under review by syndromes, which are diseases affect- the U.S. Food and Drug Administration ing the blood and bone marrow. (FDA). These medicines in development offer The medicines in development include: hope for greater survival for the thou- sands of Americans who are affected by • 98 for lymphoma, including Hodgkin these cancers of the blood. and non-Hodgkin lymphoma, which 52 affect nearly 80,000 Americans each Definitions for the cancers listed in this year. report and other terms can be found on page 27. Links to sponsor company web • 97 for leukemia, including the four sites provide more information on the major types, which affect nearly potential products. 50,000 people in the United States 24 each year. For information on the value of medi- cines, an in-depth look at current in- • 52 for myeloma, a cancer of the novation and key medical breakthroughs plasma cells, which impacts more benefiting blood cancer patients, please than 22,000 people each year in the see Medicines in Development for Leu- United States.
    [Show full text]
  • (2) Patent Application Publication (10) Pub. No.: US 2009/0226500 A1 Avelar Et Al
    US 20090226500A1 (19) United States (2) Patent Application Publication (10) Pub. No.: US 2009/0226500 A1 Avelar et al. (43) Pub. Date: Sep. 10, 2009 (54) SUTURES AND ANTI-SCARRINGAGENTS Related U.S. Application Data (75) Inventors: Rui Avelar, Vancouver (CA); (60) Provisional application No. 60/763,945, filed on Jan. Arpita Maiti, Vancouver (CA); 31, 2006. Philip M. Toleikis, Vancouver (CA); Johanne Diane Cashman, Publication Classification Vancouver (CA); David M. (51) Int. Cl. Gravett, Mountain View, CA (US) A6.1 F 2/04 (2006.01) Correspondence Address: A61 K. 3 1/135 (2006.01) SEED INTELLECTUAL PROPERTY LAW A61R 31/553 (2006.01) GROUP PLLC A61 K 31/496 (2006.01) 701 FIFTHAVENUE, SUITE 5400 A61 K 31/4164 (2006.01) SEATTLE, WA 98104-7092 (US) A61R 31/395 (2006.01) A61 K 37/426 (2006.01) (73) Assignee: Angiotech Pharmaceuticals, Inc, (52) U.S. Cl. .................... 424/423: 514/649; 514/211.08; Vancouver (CA) 514/254.07: 514/399; 514/183; 514/370 (21) Appl. No.: 12/162,572 (57) ABSTRACT (22) PCT Filed: Jan. 31, 2007 Sutures are used in combination with anti-scarring agents to (86) PCT No.: PCT/US07/02714 inhibit fibrosis between the sutures and the host tissues into which the sutures are inserted. Compositions and methods are § 371 (c)(1), described for use in reducing excessive scarring, surgical (2), (4) Date: May 6, 2009 adhesion, and other disorders. Patent Application Publication Sep. 10, 2009 Sheet 1 of 29 US 2009/0226500 A1 Patent Application Publication Sep. 10, 2009 Sheet 2 of 29 US 2009/0226500 A1 ºs||eoL-AHLKquoqonpoudp-JNLWu018=ºolZ802-14Ke8 Patent Application Publication Sep.
    [Show full text]
  • Novartis Venture Funds
    N O V A R T I S VENTURE FUnDS activityreport 2010 2 l activity report 2010 Contents 04 Introduction 06 Investment Philosophy and Focus 08 Highlights 12 Our Funds 16 Geographic Presence 18 Pipelines of Portfolio Companies 22 Medical Device and Diagnostics 24 Private Equity Portfolio 32 Board of Directors 36 Fund Management 38 Contact Information 3 l activity report 2010 mission statement Investing in innovative life science companies for patient benefit creating attractive returns for entrepreneurs and investors 4 l activity report 2010 introduction francis waldvogel Letter from the Chairman of the Medical sciences have indeed never been as cre- Novartis Venture Fund ative, diversified, and dynamic as today, emerging Ranking systems have become fashionable: from from a real melting pot where physics, material sci- air transport to the life style of cities, from health ences, chemistry, biology, genetics, informatics and care systems to universities, we can today estab- robotics converge. Miniaturization and nanoscale lish the list of the best places to be in or the most developments also move into the field. We believe dedicated services to be bestowed with. Corporate therefore that this is a time for great opportuni- Venture Funds are also part of this trend, and to our ties to develop novel diagnostic tools, therapeu- great satisfaction, the Novartis Venture Funds (NVF) tic agents and medical devices for unmet patients’ have been ranked among the top performers in the needs, and that a diversified, multidisciplinary team life science field. is a must to develop these opportunities. Ranking systems, however, have their method- ological limitations and intellectual shortcomings.
    [Show full text]
  • Prospectus for the Admission to Trading on the Regulated Market
    Prospectus for the admission to trading on the regulated market operated by Euronext Amsterdam N.V. of 2,451,766 new ordinary bearer shares with no par value vested with full dividend rights as of 1 January 2018 from a capital increase against cash contributions as resolved by the management board with the consent of the supervisory board on 9 April 2019, registered in the Commercial Register on 10 April 2019 – each with a notional par value of EUR 1.00 per share – Vivoryon Therapeutics AG Halle (Saale) International Securities Identification Number (ISIN): DE0007921835 Ticker Symbol: VVY 26 June 2019 This document constitutes a prospectus for the purposes of the admission to trading of 2,451,766 new shares (the “Admission Shares”) on the regulated market operated by Euronext Amsterdam N.V. (the “Prospectus”). This Prospectus has been prepared in the English language in accordance with the Commission Regulation (EC) No 809/2004 of 29 April 2004 (the “Prospectus Regulation”) and conforms to the requirements of the German Securities Prospectus Act (Wertpapierprospektgesetz). Vivoryon Therapeutics AG is an SME in terms of art. 2 para. 1 f) in the Prospectus Directive (Prospektrichtlinie, “Prospectus Directive”) (No 2003/71/EC) and the level of disclosure of the Prospectus is proportionate to that type of issuer (Annex XXV of the Prospectus Regulation). This Prospectus has been approved by the German Federal Financial Supervisory Authority (Bundesanstalt für Finanzdienstleistungsaufsicht) after a review for completeness of the Prospectus, including a review for coherence and comprehensibility of the presented information, according to Section 13 (1) of the German Securities Prospectus Act (Wertpapierprospektgesetz), and notified to the Netherlands Authority for the Financial Markets (Autoriteit Financiële Markten) in accordance with Section 18 (1) of the German Securities Prospectus Act (Wertpapierprospektgesetz) and the European passport mechanism set out in the Prospectus Directive.
    [Show full text]
  • Price Controls on Pharma
    Resolved: The United States federal government should impose price controls on the Pharmaceutical industry Affirmation Blocks POOR PEOPLE The pharmaceutical industry is literally killing off poor people Hartmann et. al 15 Thomas Carl "Thom" Hartmann is an American radio host, author, former psychotherapist, businessman, and progressive political commentator. Daily Take Team, 6-3-2015, "Big Pharma Is Killing Us," Truthout, http://www.truth-out.org/opinion/item/31160-big-pharma-is-killing-us //GF DDI 17 Drug company profits are literally killing people - and now even doctors are speaking out. Dr. Leonard Saltz, chief of gastrointestinal oncology at Memorial Sloan Kettering Cancer Center, rebuked the pharmaceutical industry for the sharp rise in cancer drug prices over the last decade. The median monthly price for new cancer drugs nearly doubled between 2000 and 2014 - from a monthly cost of $4,716 between 2000 and 2004 to a monthly cost of about $9,900 between 2010 and 2014. Dr. Saltz explained part of the problem: "Cancer-drug prices are not related to the value of the drug. Prices are based on what has come before and what the seller believes the market will bear." See more news and opinion from Thom Hartmann at Truthout here. And that's a neat feature of our current patent system: Drug companies don't have to worry about what people can afford to pay for a product. Because monopolies set their own prices. And that's what a patent is: a state-backed monopoly on a product. Thomas Jefferson knew that monopolies would be a threat to the people and the people's government.
    [Show full text]
  • The Los Angeles Business Journal Digital Edition
    2-Page Spread Single Page View Thumbnails | LABJ User Guide | Front Page | Table of Contents Previous Page Zoom In Zoom Out Next Page labusinessjournal.com LOS ANGELES BUSINESS JOURNALL TM DIGITAL EDITION THE COMMUNITY OF BUSINESS www.labusinessjournal.com/digital WELCOME TO THE LOS ANGELES BUSINESS JOURNAL DIGITAL EDITION To read your copy of the Digital Edition INSTRUCTION Please select a reading preference FOR PC/MAC How to read LABJ Digital Edition on iPad in iBooks: 1 TAP CENTER 2 TAP ‘OPEN WITH’ 3 TAP ‘iBOOKS’ Wait for gray bar with Wait for scroll down menu menu buttons to appear on and tap the iBooks icon. top of the PDF. Wait for PDF to load in iBOOKS. 2-Page Spread Single Page View Thumbnails | LABJ User Guide | Front Page | Table of Contents Previous Page Zoom In Zoom Out Next Page labusinessjournal.com LOS ANGELES BUSINESS JOURNAL Volume 33, Number 26 THE COMMUNITY OF BUSINESSTM June 27 - July 3, 2011 • $3.00 Up Angel Investors Talk Up Video Tech Front INTERNET: lion by Tech Coast Angels, the largest network of Vokle’s ‘virtual individual investors in the United States. auditorium’ a funding favorite. Vokle’s technology couples two hot Internet trends: social media and video advertising. By JOEL RUSSELL Staff Reporter Chief Executive Robert Kiraz explained that while Skype is the dominant Internet video service for one-to- When Republican presidential candidate Ron Paul one communications – what he called a video telephone decided to organize a virtual town hall meeting last – and services such as GoToMeeting provide a virtual week, his campaign did it with video streaming tech- boardroom, his company handles large gatherings nology from a Santa Monica startup called Vokle Inc.
    [Show full text]
  • 1 Summary of General Term Sheet Definitions
    Summary of General Term Sheet Definitions The following is a brief summary of terms and concepts commonly used in Angel and Venture Capital transactions. • Anti-Dilution Protection. The conversion price of the preferred stock will be subject to adjustment for diluting events, such as stock splits or stock dividends, and will probably also be subject to "price protection," which is adjustment upon future sales of stock at prices below the conversion price. Price protection can take many forms, from an extreme "full- ratchet" protection which lowers the conversion price to the price at which any new stock is sold, no matter the number of shares, to a broad-based "weighted average" protection which adjusts the conversion price based on a formula incorporating both the number of new shares being issued and their price. The issuance of a certain number of shares is generally excluded from this protection to cover anticipated issuances to key employees, consultants and directors. Price protection is sometimes subject to a "pay-to-play" provision, which makes the continuation of such protection for a given investor contingent on that investor purchasing at least its pro-rata share of any future issuances priced below the conversion price. • Bridge Financing. A loan is used to provide the company with operating capital while the investors conduct due diligence and negotiate the terms of the investment. The bridge loan is usually converted into equity at the next equity financing of the company. • Broad-Based Weighted Average Antidilution. A type of anti-dilution mechanism. Weighted average anti-dilution protection adjusts downward the price per share of the preferred stock of investor A due to the issuance of new preferred shares to new investor B at a price lower than the price investor A originally received.
    [Show full text]
  • The Board As a Collective Body
    Arizona Legal Studies Discussion Paper No. 07-16 The (Not So) Puzzling Behavior of Angel Investors Darian M. Ibrahim The University of Arizona James E. Rogers College of Law February 2008 THE (NOT SO) PUZZLING BEHAVIOR OF ANGEL INVESTORS Darian M. Ibrahim† __ VAND. L. REV. __ (forthcoming 2008) Draft of February 2008 Angel investors fund start-ups in their earliest stages, which creates a contracting environment rife with uncertainty, information asymmetry, and agency costs in the form of potential opportunism by entrepreneurs. Venture capitalists also encounter these problems in slightly later-stage funding, and use a combination of staged financing, preferred stock, board seats, negative covenants, and specific exit rights to respond to them. Curiously, however, traditional angel investment contracts employ none of these measures, which appears inconsistent with what financial contracting theory would predict. This Article explains this (not so) puzzling behavior on the part of angel investors, and also explains the recent move toward venture capital-like contracts as angel investing becomes more of a professional endeavor. I. INTRODUCTION .........................................................................................2 II. THE VENTURE CAPITAL INVESTMENT MODEL ........................................6 III. THE ANGEL INVESTMENT MODEL: A DEPARTURE FROM FINANCIAL CONTRACTING THEORY? ............................................................................11 A. The Need for Angels............................................................................11
    [Show full text]
  • (Not So) Puzzling Behavior of Angel Investors!!!!!!!!!!!!!!!!!!!....2-50
    Table of Contents The (Not So) Puzzling Behavior of Angel Investors!!!!!!!!!!!!!!!!!!!....2-50 Best Practice Guidance for Angel Groups " Deal Structure and Negotiation!!!!!!!!..!..51-63 TechStars Model Seed Funding Documents!!!!!!!!!!!!!!!!!!!!!!...64-65 Convertible Debt!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!.66-72 Raising Angel Money!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!.73-77 The Importance of Angel Investing in Financing the Growth of Entrepreneurial Ventures!!!!78-127 Reading 1 !"#$%!&'($)*+ ,-./,./--0+123425,+(&+ + !"#$%&'($)'*$+,--./01$2#"34/'5$'6$ 701#.$804#9('59$ !"#$"%&'(&)*#"+$,!& + !6++ + !78#9:;<8!97 6666666666666666666666666666666666666666666666666666666666666666666,5-= !!6+++ 8%*+>*78;#*+<$(!8$?+!7>*@8&*78+&9:*? 66666666666666666666,5,- !!!6++8%*+$7)*?+!7>*@8&*78+&9:*?2+$+:*($#8;#*++ A#9&+A!7$7<!$?+<978#$<8!7)+8%*9#BC 6666666666666666666666666,5,= -(&& .+/&0//1&23#&-%4/56((((((((((((((((((((((((((((((((((((((((((((((((,5,= 7(&& .#"1$8$3%"5&-%4/5&)%9/68,/%8&:3%8#";86((((((((((((((((,5/- :(&& <=>5"$%$%4&.#"1$8$3%"5&-%4/5&& )%9/68,/%8&7/+"9$3# (((((((((((((((((((((((((((((((((((((((((((((((,5/1 ,6++ 8DEFGHGIJEK+$JLMK+<IJHDENH+:MOGLJ+EO+ AGJEJNGEKKP+#EHGIJEK666666666666666666666666666666666666,5/0 "(&& .+/&0//1&23#&?3553@AB%&C/%8D#/&& :">$8"5&?D%1$%4 (((((((((((((((((((((((((((((((,5/0 *(&& )%23#,"5&ED*68$8D8/6&23#&:3%8#";8((((,53, ;(&& :3685F&:3%8#";8$%4&.+/3#F((((((((((((((((,533 1(&& G/>D8"8$3%"5&"%1&& :3D#8&E"%;8$3%6H ((((((((((((((((((((((((((((((,531 /6++ 7IJQGJEJNGEK+&IHGREHGIJO6666666666666666666666666666,53S "(&& 03%2$%"%;$"5&G/"63%6&23#&-%4/5&
    [Show full text]
  • Lenalidomide for Newly Diagnosed MM and the Incidence of Second Primary Cancer
    Key ASH Presentations Issue 7, 2012 Lenalidomide for Newly Diagnosed MM and the Incidence of Second Primary Cancer For more visit ResearchToPractice.com/5MJCASH2012 CME INFORMATION OVERVIEW OF ACTIVITY The annual American Society of Hematology (ASH) meeting is unmatched in its importance with regard to advancements in hematologic cancer and related disorders. It is targeted by many members of the clinical research community as the optimal forum in which to unveil new clinical data. This creates an environment each year in which published results and new information lead to the emergence of many new therapeutic agents and changes in the indications for existing treatments across virtually all malignant and benign hematologic disorders. As online access to posters and plenary presentations is not currently available, a need exists for additional resources to distill the information presented at the ASH annual meeting for those clinicians unable to attend but desiring to remain up to date on the new data released there. To bridge the gap between research and patient care, this CME activity will deliver a serial review of the most important emerging data sets from the latest ASH meeting, including expert perspectives on how these new evidence-based concepts can be applied to routine clinical care. This activity will assist medical oncologists, hematologists and hematology-oncology fellows in the formulation of optimal clinical management strategies and the timely application of new research findings to best-practice patient care. LEARNING OBJECTIVES • Integrate emerging research information on the use of proteasome inhibitors and immunomodulatory agents to individualize induction treatment recommendations and maintenance therapeutic approaches for elderly patients with multiple myeloma.
    [Show full text]